AstraZeneca makes a narrow escape from UK Seroquel probe
This article was originally published in Scrip
AstraZeneca's blockbuster atypical antipsychotic Seroquel (quetiapine) has been in the news quite a bit these days in relation to the multi-million-dollar settlements of its off-label probes in the US. This week, the UK's self-regulatory body for the industry, the PMCPA, published the outcome of a case on Seroquel. Although AstraZeneca escaped any sanctions by the skin of its teeth, the case raises a number of important questions for UK industry self-regulation.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.